Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-2 with Dextrose 2.5% is a peritoneal dialysis solution that removes waste products and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient driving fluid removal; electrolytes (sodium, chloride, calcium, magnesium, lactate) correct electrolyte imbalances.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
Intraperitoneal administration: 2 to 2.5 liters per exchange, typically 4 exchanges per day, with dwell times of 4-6 hours during the day and 8-12 hours overnight. Concentration selected based on ultrafiltration needs.
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
None Documented
None Documented
Not applicable; drug is not systemically absorbed. The peritoneal clearance of glucose follows first-order kinetics with a half-life of approximately 2-3 hours in the peritoneal cavity.
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Renal: negligible; drug is not absorbed systemically. The glucose is metabolized locally in peritoneal cavity and removed with dialysate outflow.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution